Focal laser ablation as clinical treatment of prostate cancer: Report from a Delphi consensus project
Göster/ Aç
Erişim
info:eu-repo/semantics/openAccessAttribution 4.0 Internationalhttps://creativecommons.org/licenses/by/4.0/Tarih
2019Yazar
van Luijtelaar, AnnemarijkeGreenwood, Bernadette Marie
Ahmed, Hashim Uddin
Barqawi, Al Baha
Barret, Éric
Bomers, Joyce G.R.
Brausi, Maurizio
Choyke, Peter L.
Cooperberg, Matthew R.
Eggener, Scott E.
Feller, John Francis
Frauscher, Ferdinand
George, Arvin Koruthu
Hindley, Richard Graham
Jenniskens, Sjoerd F.M.
Klotz, Laurence
Kovacs, Gyoergy
Lindner, Uri
Loeb, Stacy
Margolis, Daniel Jason Aaron
Marks, Leonard S.
May, Stuart
McClure, Timothy D.
Montironi, Rodolfo
Nour, Sherif Gamal
Oto, Aytekin
Polascik, Thomas James
Rastinehad, Ardeshir R.
de Reyke, T. M.
Reijnen, Jeroen Sebastiaan
de la Rosette, Jean J. M. C. H.
Sedelaar, John Pieter Michiel
Sperling, Dan S.
Walser, Eric M.
Ward, John F.
Villers, Arnauld A.
Ghai, Sangeet
Fütterer, Jürgen Jacobus
Üst veri
Tüm öğe kaydını gösterKünye
van Luijtelaar, A., Greenwood, B. M., Ahmed, H. U., Barqawi, A. B., Barret, É., Bomers, J. G.R. ... Fütterer, J. J. (2019). Focal laser ablation as clinical treatment of prostate cancer: Report from a Delphi consensus project. World Journal of Urology, 37(10), 2147-2153. https://dx.doi.org/10.1007/s00345-019-02636-7Özet
Purpose: To define the role of focal laser ablation (FLA) as clinical treatment of prostate cancer (PCa) using the Delphi consensus method. Methods: A panel of international experts in the field of focal therapy (FT) in PCa conducted a collaborative consensus project using the Delphi method. Experts were invited to online questionnaires focusing on patient selection and treatment of PCa with FLA during four subsequent rounds. After each round, outcomes were displayed, and questionnaires were modified based on the comments provided by panelists. Results were finalized and discussed during face-to-face meetings. Results: Thirty-seven experts agreed to participate, and consensus was achieved on 39/43 topics. Clinically significant PCa (csPCa) was defined as any volume Grade Group 2 [Gleason score (GS) 3+4]. Focal therapy was specified as treatment of all csPCa and can be considered primary treatment as an alternative to radical treatment in carefully selected patients. In patients with intermediate-risk PCa (GS 3+4) as well as patients with MRI-visible and biopsy-confirmed local recurrence, FLA is optimal for targeted ablation of a specific magnetic resonance imaging (MRI)-visible focus. However, FLA should not be applied to candidates for active surveillance and close follow-up is required. Suitability for FLA is based on tumor volume, location to vital structures, GS, MRI-visibility, and biopsy confirmation. Conclusion: Focal laser ablation is a promising technique for treatment of clinically localized PCa and should ideally be performed within approved clinical trials. So far, only few studies have reported on FLA and further validation with longer follow-up is mandatory before widespread clinical implementation is justified.